Evaluation of clinical characteristics of severe acute respiratory syndrome coronavirus 2 and reactivation status in Rwanda

Principal investigator: clarisse Musanabaganwa
Check PI profile

Investigators

Clarisse Musanabaganwa, Sabin Nsanzimana, Leo Mutesa, Jean Baptiste Mazarati, Yvan Mwikarago, Alice Kabanda, Claude Semuto, Claude Mambo Muvunyi, Etienne Mpabuka, Noela Bigirimana, Annette Uwineza, Majidi Habimana, Raissa Muvunyi, David Turatsinze, Menelas Nkeshimana, Thierry Nyatanyi, Erneste Nahayo, Daniel Nyamwasa, Angus Nassir

Study information

  • Research Area: COVID-19
  • Research type: Prospective
  • Start date: May 02, 2020
  • End date: May 02, 2022

Study aim of the objectives

Aim: to evaluate the clinical characteristics of the SARS-CoV-2 reactivation in Rwanda. Specific objectives: To determine the clinical features of SARS-CoV-2 r recovered and reactivated patients in Rwanda; To identify the potential risk factors of SARS-CoV-2 reactivation in Rwanda


Study setting/Area (Location)

All COVID-19 treatment sites in Rwanda

Implementing institution

Rwanda Biomedical Center, University of Rwanda and Referral hospitals

Department/Division

Research, Innovation and Data Science, National Reference, Center for Human genetics, CHUK and Kacyiru Hospital

Impact on Policy

The findings will inform treatment guidelines of COVID-19

Study implementation progress

Related research

Login
Support